**Title of Study: A Phase 2 double-blind placebo-controlled study investigating the safety and efficacy of EDP1815 in the treatment of patients hospitalized with SARS-CoV-2 Infection**

The **purpose of the research** is to study if EDP1815 is safe and helps treat people with COVID-19.

 This drug is a strain of bacteria that is normally found in the human gut and is designed to lower inflammation in the body.

|  |
| --- |
| **INCLUSION/EXCLUSION CRITERIA** |
| **Inclusion** |  | **Exclusion** |
| 1. COVID + at screening by PCR
2. Admitted < 36 hours
3. Age 18-65
4. Require supplemental oxygen at baseline
 | 1. contraindication/AE to *P histicola* or any excipients
2. Chronic hypoxia or significant chronic respiratory dz
3. ICU or CPAP
4. Primary immunodeficiency
5. On chronic immunosuppressant
6. CKD4/5 or GFR<30
7. Chronic liver dz with ALT, AST> 5x ULN
8. Preexisting significant GI tract dz affecting absorption
9. Significant cardiac dz (unstable angina, acute MI) <6 wks prior to screening
10. GI signs/sxs = CTCAE v5.0 GI d/o, grade 3 or 4
 |
|  |
|  **Day 1, 4 and 7 LABS**  | **Potential side effects** |
| CBC, CMP Ferritin, D-Dimer, LDH, CRP, Troponin, , pregnancy test for women of childbearing potential | * headache diarrhea
* Pain or bruise from blood draw
 |
|  |
|  | **Treatment duration** |
| * **Total 14 days of EDP1815 or placebo**
* **1;1 EDP1815/placebo**
 |
| **Patient can be discharged earlier. Patient can take the remaining study medication at home.** **Study team will contact patient via phone.**  | **Contact info:****Dr Sugeet Japal****Dr Ting-Yu Jih** **Dr Jared Radbel** **Fei Chen RN 732-318-1411 (24 hrs.) text ok**  |

No prohibited concomitant medications pertaining to treatment/management of COVID19